Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2012-09-11 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2012-09-11 English
FORM 10-Q/A
Interim / Quarterly Report Q2 2012
2012-09-07 English
SCHEDULE 13D/A
Major Shareholding Notification
2012-08-28 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a joint venture agreement), unregistered sales of equity securities, and related board approvals. There are no financial statements or detailed financial data presented, only descriptions of corporate events and a press release attached as an exhibit. The document length is 3397 characters, which is relatively short and consistent with an 8-K filing. This type of filing is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Capital/Financing Update. Therefore, the appropriate classification is RNS with high confidence.
2012-08-21 English
FORM 10-Q
Interim / Quarterly Report Q2 2012
2012-08-09 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an amendment to a material definitive agreement related to board composition and rights of a significant shareholder. It includes the execution date, parties involved, and a summary of the amendment. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a proxy statement, earnings release, or other specific report type. It is a regulatory filing announcing a material event, consistent with the purpose of Form 8-K filings. Given the nature and content, the appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters and it includes an exhibit attachment, but the main content is the announcement of the amendment, not the full agreement or financial report itself.
2012-08-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.